Australia's most trusted
source of pharma news
Friday, 21 March 2025
Posted 21 March 2025 AM
An additional 55 children living with cystic fibrosis (CF) are now eligible to receive Trikafta in New Zealand after Vertex notched two new indications for the triplet therapy.
Trikafta was first consented by Medsafe in 2021 for use in people with CF aged six years and older with at least one F508del mutation in the CFTR gene.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.